Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?

Sulphonylureas (SU) form an important role in management of people with type 2 diabetes. This safety history of SU was tainted for various reasons, the predominant one being lack of demonstration of cardiovascular safety. Since its introduction, SU's have never been subjected to a formal study...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Mathew, Kalra, Sanjay, Nair, Tiny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Opinion Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474120/
https://www.ncbi.nlm.nih.gov/pubmed/32861392
http://dx.doi.org/10.1016/j.ihj.2020.07.009
_version_ 1783579287102685184
author John, Mathew
Kalra, Sanjay
Nair, Tiny
author_facet John, Mathew
Kalra, Sanjay
Nair, Tiny
author_sort John, Mathew
collection PubMed
description Sulphonylureas (SU) form an important role in management of people with type 2 diabetes. This safety history of SU was tainted for various reasons, the predominant one being lack of demonstration of cardiovascular safety. Since its introduction, SU's have never been subjected to a formal study for its cardiovascular safety. The cardiovascular safety of SUs was derived from small, inadequately powered randomised controlled trials (RCT) and observational studies. CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) trial planned as a cardiovascular outcome trial randomised people with type 2 diabetes and high cardiovascular risk to Linagliptin and Glimepiride. This opinion paper outlines the salient features of this landmark trial and its implications in general cardiology practice.
format Online
Article
Text
id pubmed-7474120
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74741202020-09-15 Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy? John, Mathew Kalra, Sanjay Nair, Tiny Indian Heart J Opinion Paper Sulphonylureas (SU) form an important role in management of people with type 2 diabetes. This safety history of SU was tainted for various reasons, the predominant one being lack of demonstration of cardiovascular safety. Since its introduction, SU's have never been subjected to a formal study for its cardiovascular safety. The cardiovascular safety of SUs was derived from small, inadequately powered randomised controlled trials (RCT) and observational studies. CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) trial planned as a cardiovascular outcome trial randomised people with type 2 diabetes and high cardiovascular risk to Linagliptin and Glimepiride. This opinion paper outlines the salient features of this landmark trial and its implications in general cardiology practice. Elsevier 2020 2020-07-17 /pmc/articles/PMC7474120/ /pubmed/32861392 http://dx.doi.org/10.1016/j.ihj.2020.07.009 Text en © 2020 Cardiological Society of India. Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Opinion Paper
John, Mathew
Kalra, Sanjay
Nair, Tiny
Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
title Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
title_full Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
title_fullStr Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
title_full_unstemmed Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
title_short Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
title_sort modern sulphonylureas and cardiovascular adverse effects: will carolina put an end to the controversy?
topic Opinion Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474120/
https://www.ncbi.nlm.nih.gov/pubmed/32861392
http://dx.doi.org/10.1016/j.ihj.2020.07.009
work_keys_str_mv AT johnmathew modernsulphonylureasandcardiovascularadverseeffectswillcarolinaputanendtothecontroversy
AT kalrasanjay modernsulphonylureasandcardiovascularadverseeffectswillcarolinaputanendtothecontroversy
AT nairtiny modernsulphonylureasandcardiovascularadverseeffectswillcarolinaputanendtothecontroversy

Ejemplares similares